.png)
.png)
Total amount raised
Latest funding date
Location
Joseph Bolen is the CEO of Orna Therapeutics, a pioneering company in the field of RNA therapeutics. With a distinguished scientific career that includes senior leadership roles at Orna Therapeutics and foundational research at the National Cancer Institute, Bolen brings deep expertise in biochemical oncology and life sciences to his role leading the company.
Who is the CEO of Orna Therapeutics?
Joseph Bolen is a seasoned life sciences leader with a career rooted in rigorous scientific research and executive leadership. Currently serving as the CEO of Orna Therapeutics, Bolen brings a wealth of experience in RNA biology and oncology to the role. His background spans decades of scientific and organizational leadership, positioning him to guide Orna Therapeutics in its mission to advance innovative RNA-centric approaches to medicine.
Prior to assuming the CEO role, Bolen held successive senior scientific leadership positions at Orna Therapeutics, demonstrating a deep commitment to the company's vision and platform.
Work History
Joseph Bolen's work history reflects a career built on scientific leadership and executive responsibility across the life sciences. Here is a detailed list of his positions:
- Orna Therapeutics - Chief Executive Officer (March 2025 - Present)
- Orna Therapeutics - Chief Scientific Officer (November 2024 - March 2025)
- Orna Therapeutics - Chief Science Innovation Officer (May 2024 - March 2025)
- National Cancer Institute (NCI) - Chief, Biochemical Oncology Section, Laboratory of Tumor Virus Biology (September 1980 - May 1990)
Education History
Joseph Bolen's academic foundation has supported a distinguished career in biochemical research and life sciences leadership.
When did Joseph Bolen join Orna Therapeutics?
Joseph Bolen assumed the role of Chief Executive Officer at Orna Therapeutics in March 2025. His appointment to the CEO position followed his tenure in senior scientific leadership roles at the company, reflecting a natural progression built on his deep familiarity with Orna Therapeutics' platform and strategic direction.
